Evelo Biosciences, Inc. · OTC:EVLO

Evelo Biosciences — Technical Presentation (January 2021)

15 slides from Evelo Biosciences's technical presentation, Jan 20, 2021

  1. Slide 1: Complete Phase 1b Dataset: EDP1815 in Atopic Dermatitis

    Complete Phase 1b Dataset: EDP1815 in Atopic Dermatitis January 20, 2021

  2. Slide 2: Legal disclaimer

    Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including

  3. Slide 3: Phase 1b clinical trial design

    Phase 1b clinical trial design Trial Summary • Double-blind, placebo-controlled trial of 24 patients • Mild and moderate atopic dermatitis*, randomized 2:1 (active : placebo) • 56 days of oral administration of enteric capsule formulation, follow-up at day 70 • Once daily • No active topical treatme

  4. Slide 4: No topical therapies required for patients for >8 weeks

    No topical therapies required for patients for >8 weeks • No topical steroids permitted at any point • Topical emollients permitted to be used only if the patient was already using regularly prior to entry into trial • Low rate of topical emollients use: • Placebo: 2 of 8 (25%) applied emollient reg

  5. Slide 5: Improvements in EASI, IGA*BSA, and SCORAD at day 56

    Improvements in EASI, IGA*BSA, and SCORAD at day 56 5 * Clinical Measure Treatment Difference at Day 56 EASI 52% (p=0.062) IGA*BSA 65% (p=0.022) SCORAD 55% (p=0.043)

  6. Slide 6: EASI: 10/16 patients on EDP1815 improved at day 56

    EASI: 10/16 patients on EDP1815 improved at day 56 6 Patients (n=24)

  7. Slide 7: 44% of EDP1815 patients achieved EASI50

    44% of EDP1815 patients achieved EASI50 7 Clinical Measure Placebo EDP1815 EASI50 day 56 0/8 (0%) 4/16 (25%) EASI50 day 70 0/8 (0%) 7/16 (44%) EASI50 response at day 70 Placebo EDP1815 Intervention

  8. Slide 8: IGA*BSA: patients achieved a >50% improvement at day 56 with EDP1815

    IGA*BSA: 6 patients achieved a >50% improvement at day 56 with EDP1815 8 50% Improvement Patients (n=24)

  9. Slide 9: Clinically meaningful improvements in Patient-Reported Outcomes at day 56

    Clinically meaningful improvements in Patient-Reported Outcomes at day 56, including itch and sleep 9 Patient-Reported Outcome EDP1815 Mean change, day 56 (mean % change per patient) Placebo Mean change, day 56 (mean % change per patient) DLQI (Dermatology Life Quality Index) –3.6* (-35%) –0.3 (+46%

  10. Slide 10: Efficacy of oral EDP1815 in atopic dermatitis

    Efficacy of oral EDP1815 in atopic dermatitis 10 Patient on once daily oral EDP1815 and no topical treatments: before and after (patient achieved EASI50 score) Before, day 0 After, day 56

  11. Slide 11: Conclusions

    Conclusions 1. Consistent results observed across all atopic dermatitis measures 2. Progressing into Phase 2 clinical trial in atopic dermatitis 3. EDP1815 has now shown clinical activity in both psoriasis and atopic dermatitis patients 11

  12. Slide 12: Patient need in mild and moderate atopic dermatitis

    Patient need in mild and moderate atopic dermatitis 12

  13. Slide 13: Hundreds of millions of patients worldwide live with atopic dermatitis

    Hundreds of millions of patients worldwide live with atopic dermatitis, most with no meaningful treatments “1 in 3 takes one or more hours per day to treat their AD” 13Atopic Dermatitis: Survey of 192 patients from the National Eczema Association, 2016 https://nationaleczema.org/in-your-words-survey

  14. Slide 14: SINTAX medicines potentially applicable across spectrum of inflammatory diseases

    14 SINTAX medicines potentially applicable across spectrum of inflammatory diseases- plan to capture full breadth in staged manner Th2 focused • Allergic bronchopulmonary aspergillosis • Allergic rhinitis • Bullous pemphigoid • Chronic spontaneous urticaria • Eosinophilic esophagitis • Eosinophilic

  15. Slide 15: Pipeline is rich in anticipated near-term clinical catalysts

    Pipeline is rich in anticipated near-term clinical catalysts 15 Candidate Catalyst EDP1815 Psoriasis 1Q 2021: Phase 1b tablet formulation trial initiation 3Q 2021: Phase 1b tablet formulation data 2Q 2021: Phase 2 interim data 2H 2021: Full Phase 2 dataset 1H 2022: Phase 3 initiation* EDP1815 Atopic

Evelo Biosciences — Technical Presentation (January 2021) on 6ix